Literature DB >> 10602002

IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras / MAP kinase pathway.

D Puthier1, R Bataille, M Amiot.   

Abstract

Mcl-1 is an anti-apoptotic member of the Bcl-2 family which is tightly regulated during myeloid and B cell differentiation. We have recently reported that Mcl-1 is expressed in human myeloma cells and that Mcl-1 and Bcl-x(L) expression are correlated. In the current study, we demonstrate that IL-6, a survival factor for the human myeloma cell line MDN, rapidly up-regulates Mcl-1 whereas it has no effect on Bcl-2 protein level. In MDN cells, IL-6 induces both extracellular signal-regulated protein kinase (ERK)1,2 and STAT3 activation whereas STAT1 and STAT5 activation remains undetectable. Furthermore, while investigating the IL-6 signaling pathway leading to Mcl-1 up-regulation, we show that a janus kinase (JAK)-2 inhibitor is able to inhibit both STAT3 activation and Mcl-1 up-regulation whereas an MAP/ERK kinase (MEK) inhibitor has no effect. In conclusion, our data suggest the involvement of the JAK / STAT pathway but not of the Ras / mitogen-activated protein (MAP) kinase pathway in IL-6-induced Mcl-1 up-regulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10602002     DOI: 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  68 in total

1.  Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer.

Authors:  Shunichi Tsujitani; Hiroaki Saito; Toshiro Wakatsuki; Masahide Ikeguchi; Ken Shirabe; Masaru Morita; Yoshihiro Kakeji; Tokujiro Yano; Yoshihiko Maehara
Journal:  Surg Today       Date:  2011-12-06       Impact factor: 2.549

2.  Overexpression of mcl-1 attenuates liver injury and fibrosis in the bile duct-ligated mouse.

Authors:  Alisan Kahraman; Justin L Mott; Steven F Bronk; Nathan W Werneburg; Fernando J Barreyro; Maria E Guicciardi; Yuko Akazawa; Karen Braley; Ruth W Craig; Gregory J Gores
Journal:  Dig Dis Sci       Date:  2008-12-03       Impact factor: 3.199

Review 3.  Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Authors:  Tariq I Mughal; Saulius Girnius; Steven T Rosen; Shaji Kumar; Adrian Wiestner; Omar Abdel-Wahab; Jean-Jacques Kiladjian; Wyndham H Wilson; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-02-17

4.  Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.

Authors:  Vikas A Gupta; Shannon M Matulis; Jason E Conage-Pough; Ajay K Nooka; Jonathan L Kaufman; Sagar Lonial; Lawrence H Boise
Journal:  Blood       Date:  2017-02-01       Impact factor: 22.113

5.  Molecular alterations in primary prostate cancer after androgen ablation therapy.

Authors:  Carolyn J M Best; John W Gillespie; Yajun Yi; Gadisetti V R Chandramouli; Mark A Perlmutter; Yvonne Gathright; Heidi S Erickson; Lauren Georgevich; Michael A Tangrea; Paul H Duray; Sergio González; Alfredo Velasco; W Marston Linehan; Robert J Matusik; Douglas K Price; William D Figg; Michael R Emmert-Buck; Rodrigo F Chuaqui
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

Review 6.  Signaling Pathways and Emerging Therapies in Multiple Myeloma.

Authors:  Vijay Ramakrishnan; Anita D'Souza
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

Review 7.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

8.  R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells.

Authors:  Michael P Kline; S Vincent Rajkumar; Michael M Timm; Teresa K Kimlinger; Jessica L Haug; John A Lust; Philip R Greipp; Shaji Kumar
Journal:  Exp Hematol       Date:  2008-03-17       Impact factor: 3.084

9.  The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells.

Authors:  Qun Zhou; Yuan Yao; Solveig G Ericson
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

10.  Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.

Authors:  V Ramakrishnan; M Timm; J L Haug; T K Kimlinger; L E Wellik; T E Witzig; S V Rajkumar; A A Adjei; S Kumar
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.